In a phase IB multicenter dose determination clinical study, a humanized monoclonal antibody targeting DKK1, BHQ880 in combination with ZA and anti-myeloma treatment increased bone strength and density [235]. The gene discussed is DKK1; the disease is plasma cell myeloma.